CVS Has 'Real Value,' Jim Cramer Says: Micron Had An 'Amazing' Quarter
Portfolio Pulse from Avi Kapoor
Jim Cramer discussed several stocks on CNBC's 'Mad Money Lightning Round.' He sees value in CVS Health, praises Micron Technology's quarter, and recommends buying Robinhood and Modine Manufacturing. He advises against American Tower and considers ADMA Biologics speculative.
October 11, 2024 | 1:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Jim Cramer sees real value in CVS Health, supported by Barclays' upgrade and increased price target.
Cramer's positive view and Barclays' upgrade with a higher price target suggest a bullish sentiment, likely boosting CVS's stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Cramer recommends buying Robinhood, supported by Piper Sandler's positive rating.
Cramer's buy recommendation and Piper Sandler's positive rating suggest a favorable short-term outlook for Robinhood.
CONFIDENCE 80
IMPORTANCE 50
RELEVANCE 60
POSITIVE IMPACT
Cramer is optimistic about Howmet Aerospace, calling it one of the greatest stocks of his time.
Cramer's strong endorsement suggests a positive outlook, though recent price action was negative.
CONFIDENCE 75
IMPORTANCE 40
RELEVANCE 50
POSITIVE IMPACT
Cramer recommends buying Modine Manufacturing, highlighting its strengths as a metal-bending company.
Cramer's recommendation and recent analyst upgrades suggest a positive outlook for Modine.
CONFIDENCE 75
IMPORTANCE 40
RELEVANCE 50
POSITIVE IMPACT
Cramer recommends buying Micron Technology after an 'amazing' quarter, despite a slight price target reduction by Keybanc.
Cramer's positive remarks on Micron's performance, despite a minor price target cut, indicate a positive short-term outlook.
CONFIDENCE 85
IMPORTANCE 60
RELEVANCE 70
NEGATIVE IMPACT
Cramer considers ADMA Biologics a 'very speculative' stock, despite Cantor Fitzgerald's positive rating.
Cramer's cautionary stance on ADMA as speculative may deter risk-averse investors, despite positive analyst ratings.
CONFIDENCE 70
IMPORTANCE 30
RELEVANCE 40
NEGATIVE IMPACT
Cramer advises against investing in American Tower, despite Barclays' positive rating and increased price target.
Cramer's negative stance contrasts with Barclays' positive outlook, potentially leading to mixed investor sentiment.
CONFIDENCE 80
IMPORTANCE 50
RELEVANCE 60